Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Filters applied. Clear all Your search was processed without automatic term mapping because it retrieved zero results.
Clinical Trial
. 2018 Jul;59(7):1634-1643.
doi: 10.1080/10428194.2017.1397661. Epub 2017 Nov 22.

Efficacy and Safety of Native Versus Pegylated Escherichia Coli Asparaginase for Treatment of Adults With High-Risk, Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia

Affiliations
Clinical Trial

Efficacy and Safety of Native Versus Pegylated Escherichia Coli Asparaginase for Treatment of Adults With High-Risk, Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia

Josep-Maria Ribera et al. Leuk Lymphoma. .

Abstract

Native or pegylated (PEG) asparaginase (ASP) are commonly used in treatment of acute lymphoblastic leukemia (ALL), but have been scarcely compared in the same trial in adult patients. Native vs. PEG-ASP administered according to availability in each center were prospectively evaluated in adults with high-risk ALL. Ninety-one patients received native ASP and 35 PEG-ASP in induction. No significant differences were observed in complete remission, minimal residual disease levels after induction and after consolidation, disease-free survival, and overall survival. No significant differences in grades 3-4 toxicity were observed in the induction period, although a trend for higher hepatic toxicity was observed in patients receiving PEG-ASP. In this trial the type of ASP did not influence patient response and outcome.

Keywords: Adult acute lymphoblastic leukemia; Escherichia coli asparaginase; efficacy; native; pegylated; toxicity.

Similar articles

See all similar articles

Cited by 3 articles

Publication types

MeSH terms

LinkOut - more resources

Feedback